Skip to main content

Table 4 Effect of Doxorubicin (DOX) and AHE treatment on cardiac tissue antioxidant enzymes

From: Acacia hydaspica R. Parker prevents doxorubicin-induced cardiac injury by attenuation of oxidative stress and structural Cardiomyocyte alterations in rats

Group POD (U/min) SOD (U/mg protein) CAT (U/min) QR (nM/min/mg protein)
Control 10.66 ± 0.538b 1.146 ± 0.037b 15.76 ± 0.118b 137.5 ± 0.735b
DOX 5.970 ± 0.560a 0.7845 ± 0.027a 9.025 ± 0.090a 83.45 ± 0.416a
AHE alone 10.92 ± 0.531b 1.145 ± 0.049b 15.66 ± 0.197b 137.7 ± 0.392b
DOX + AHE (200) 8.63 ± 0.363a,b** 0.9799 ± 0.027b* 12.87 ± 0.297a,b,d 117.6 ± 0.652a,b,d
DOX + AHE (400) 9.600 ± 0.3464b 1.042 ± 0.025b** 14.95 ± 0.216b,c 131.0 ± 1.621a**,b,c
DOX + Sily 9.590 ± 0.3406b 1.055 ± 0.053b** 14.93 ± 0.256b 130.4 ± 0.7148a,b
  1. Values expressed as mean ± SEM
  2. aSignificance at p < 0.0001 Vs. control group
  3. bSignificance at p < 0.0001 Vs. Doxorubicin (DOX) group
  4. cSignificance at p < 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group
  5. dSignificance at p < 0.0001 of AHE co-treatment groups Vs DOX + Sily group
  6. *, **Significant difference at p < 0.05 and p < 0.001 respectively. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey’s multiple comparison tests). Sily-Silymarin
\